Pharmacokinetic Evaluation of QRL-101 Formulations in Healthy Subjects for Amyotrophic Lateral Sclerosis (ALS)

The primary objective of this study is to evaluate the **pharmacokinetics** of three formulations of QRL-101 in healthy participants. Understanding the pharmacokinetics is crucial as it provides insights into the absorption, distribution, metabolism, and excretion of the drug, which are essential for determining the appropriate dosage and ensuring safety and efficacy in future clinical applications. This study is particularly relevant for conditions such as **Amyotrophic Lateral Sclerosis (ALS)**, where effective treatment options are limited. No secondary objectives are specified for this study.

The clinical trial involves participants diagnosed with **Amyotrophic Lateral Sclerosis (ALS)**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. The trial population was selected to include a vulnerable population, although specific details regarding the total number of participants have not been provided by the sponsor. Participants' general health status, lifestyle considerations such as diet, physical activity, or habits, and specific inclusion or exclusion criteria have not been disclosed. The trial aims to gather data from a diverse group of individuals affected by ALS, ensuring a comprehensive understanding of the disease's impact across different demographics.

The clinical trial is designed to evaluate the **pharmacokinetics** of three formulations of QRL-101 in healthy participants. This study is a Phase 3 trial, which is typically conducted to confirm the effectiveness of a treatment, monitor side effects, and collect information that will allow the treatment to be used safely. The trial is structured as a randomized, double-blind, controlled study, ensuring that neither the participants nor the researchers know which formulation is being administered, thus minimizing bias. The estimated recruitment start date is February 11, 2025, with an anticipated end date of April 26, 2025, indicating a relatively short trial duration.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve a comprehensive evaluation to ensure participants meet the necessary health standards for inclusion in the study. Following the screening, participants will be randomly assigned to receive one of the three QRL-101 formulations. Throughout the trial, there will be scheduled follow-up visits to monitor the participants' health, assess the pharmacokinetics of the formulations, and ensure adherence to the study protocol. The end-of-study visit will conclude the trial, where final assessments will be conducted to gather data on the primary and secondary endpoints.

The expected length of participant involvement is approximately two and a half months, from the start of recruitment to the end of the study. Conditions that may lead to early termination from the study include adverse reactions to the formulations, non-compliance with the study protocol, or withdrawal of consent by the participant. The trial aims to provide valuable data on the pharmacokinetics of QRL-101, contributing to the understanding of its potential use in treating **Amyotrophic Lateral Sclerosis (ALS)**.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this study, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used alongside the experimental medication. The data does not provide details on any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring. Consequently, the trial documentation lacks comprehensive information on the treatment protocols and participant management strategies.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on February 11, 2025, with an estimated completion date of April 26, 2025. The efficacy of the investigational treatment will be evaluated using specific parameters, although these parameters are not detailed in the provided data. The trial will follow a structured methodology to ensure the accurate collection and analysis of efficacy data. The trial's design and execution will adhere to rigorous standards typical of Phase 3 studies, ensuring that the results are reliable and scientifically valid. The trial's primary focus is to determine the treatment's effectiveness in the specified medical condition, which is not explicitly mentioned in the data. The study will be conducted in accordance with established clinical trial protocols, ensuring that all assessments are performed consistently and objectively.